CordenPharma is pleased to announce a collaboration with biosimulytics that combines experimental polymorphism investigations with advanced Crystal Structure Prediction (CSP) capabilities. By bringing together laboratory-based solid-state expertise and predictive computational modeling, the collaboration provides customers with a more complete understanding of solid-form landscapes and supports more confident decision-making throughout pharmaceutical development.
Why polymorphism matters in pharmaceutical development
Polymorphism describes the ability of an active pharmaceutical ingredient (API) to exist in more than one crystalline solid form. These different forms can behave differently in development and manufacturing, including in terms of solubility, dissolution rate, stability, processability, and ultimately drug product performance. Identifying, understanding, and controlling solid forms early is therefore critical to reducing development risk and establishing robust manufacturing processes.
Combining predictive modeling with experimental expertise
Through this collaboration, biosimulytics contributes computational predictions of potential polymorphic forms using CSP technology, while CordenPharma’s Solid State Centre of Excellence performs experimental solid-state screening and characterization to identify and validate accessible forms under real-world conditions. These complementary approaches provide a broader view of the polymorphic landscape and help strengthen confidence in solid-form selection and control strategies.
CordenPharma’s SVP, Commercial Head BU Innovative Synthesis Dr. Stephen Houldsworth (left) and Peter Doyle, CEO of biosimulytics (right) present a poster at BOS Basel 2026: Two Worlds, One Polymorph Strategy: Experimental Screening Meets Crystal Structure Prediction.
Customer benefits: earlier insight, stronger control, lower development risk
Part of CordenPharma’s broader development support
The collaboration aligns with CordenPharma’s broader strategy of supporting efficient API development, technology transfer, and commercial manufacturing through specialized Centers of Excellence. Alongside the Solid State Centre of Excellence, which provides expertise in crystallization, solid forms, and polymorphism, CordenPharma’s Flow Chemistry Centre of Excellence offers advanced solutions for process intensification and route development. Together, these complementary capabilities help customers address complex development challenges, accelerate process understanding, and establish robust, scalable manufacturing processes across the entire drug lifecycle.
Strong early results and next steps
Initial joint case studies have demonstrated a strong correlation between experimental outcomes and computational predictions, providing valuable insight into polymorphic accessibility and solid-form risk. The teams are currently preparing scientific publications that will further highlight the benefits of combining experimental and in-silico approaches in pharmaceutical development.
Executive perspectives
“We believe the future of solid-state development lies in integrating cutting-edge computational tools with deep experimental expertise,” said Stephen Houldsworth, Senior Vice President, Innovative Synthesis, CordenPharma. “By combining these complementary capabilities, we can help our customers make more informed decisions and reduce development risk.”
Peter Doyle, CEO of biosimulytics, added: “Bringing predictive solid-form modeling together with comprehensive laboratory investigations provides a powerful framework for understanding polymorphic behavior and strengthening development strategies.”
As pharmaceutical molecules become increasingly complex, integrated approaches that combine experimental science with predictive computational technologies are expected to play a growing role in de-risking development programs. Through this collaboration, CordenPharma and biosimulytics aim to provide customers with enhanced confidence in solid-form selection, robust control strategies, and a stronger path toward successful commercialization.
Read the full poster from BOS Basel – 30 June – 1 July 2026
About CordenPharma’s Solid State Centre of Excellence
CordenPharma’s Solid State Centre of Excellence supports drug substance and drug product development through polymorph screening, crystallization process development, salt and co-crystal investigations, solid-form characterization, and scale-up support. The team helps customers identify, understand, and control the optimal solid form throughout the product lifecycle.
About biosimulytics
biosimulytics develops computational technologies for solid-form risk assessment and Crystal Structure Prediction, helping pharmaceutical companies understand polymorphic landscapes and make more informed development decisions from early development onward.
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.